Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference [Yahoo! Finance]
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics [Yahoo! Finance]
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference